PLUS1
1.50
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Market Closed
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
Best deals to access real time data! |
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
Canna Trader Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CytoDyn Inc (QB) | CYDY | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 1.50 | 06:53:22 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.50 | USD |
Period:
Draw Mode:
CytoDyn Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 936.19M | 624.13M | 377.49M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 35.77M | $ - | - | - | - |
CytoDyn (QB) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYDY Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.44 | 1.58 | 1.36 | 1.45 | 1,554,618 | 0.06 | 4.17% |
| 1 Month | 2.33 | 2.43 | 1.35 | 1.72 | 1,928,346 | -0.83 | -35.62% |
| 3 Months | 1.57 | 2.54 | 1.23 | 1.63 | 2,176,048 | -0.07 | -4.46% |
| 6 Months | 3.28 | 3.40 | 1.23 | 1.88 | 2,355,479 | -1.78 | -54.27% |
| 1 Year | 2.70 | 7.70 | 1.23 | 3.28 | 3,445,458 | -1.20 | -44.44% |
| 3 Years | 0.53 | 10.01 | 0.0552 | 3.15 | 3,031,411 | 0.97 | 183.02% |
| 5 Years | 0.675 | 10.01 | 0.0552 | 3.02 | 1,923,111 | 0.825 | 122.22% |
CytoDyn (QB) Description
| CytoDyn Inc. is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of Human Immunodeficiency Virus (HIV), Cancer, and Immunology. |
